HOUSTON, Jun 06, 2012 (BUSINESS WIRE) –The attorneys of Blizzard, McCarthy & Nabers, LLP, a law firm specializing in pharmaceutical and medical device litigation, is pursuing vaginal mesh lawsuits against Ethicon and Johnson & Johnson. Blizzard, McCarthy & Nabers has played a significant role in many medical device lawsuits and has the knowledge and resources necessary to handle these complex lawsuits.
Ethicon, inc., a subsidiary of Johnson & Johnson, has announced that it will no longer be selling four of its vaginal mesh products following a substantial number of reported injuries and an increasing number of related lawsuits.
the products affected are the Gynecare TVT Secur(TM) System, Gynecare Prosima(TM) Pelvic Floor Repair System, Gynecare Prolift(TM) Pelvic Floor Repair System, and Gynecare Prolift+M(TM) Pelvic Floor Repair System. these products belong to a family of products commonly known as vaginal mesh or transvaginal mesh, a surgically implanted plastic mesh introduced to the market in the early 2000′s and designed to restore organ support in women with pelvic organ prolapse and to prevent leakage in women with stress urinary incontinence.
In the years following the widespread use of vaginal mesh, the FDA began receiving reports of serious injuries suffered by women with mesh implants. Many women reported complications such as mesh erosion and exposure, scarring, chronic infections, organ perforation, bleeding, and painful sexual intercourse. In January of 2012, the FDA ordered manufacturers of vaginal mesh to conduct further research into the safety of their products.
“Many women have told us that this mesh has destroyed their lives, that they have experienced severe pain and emotional distress, and their marriages and relationships have been severely disrupted,” says Ed Blizzard, an attorney with Blizzard, McCarthy & Nabers. “Once the mesh erodes inside a woman’s body, removing all of the mesh is extremely difficult and can require multiple operations. some surgeons find that it is impossible to fully remove the mesh.”
“The Prolift implant was put on the market without FDA approval or adequate testing. Yet the surgery was marketed to women as a simple and routine outpatient procedure,” says Blizzard. “They were never informed of the dangers. Ethicon was right to pull these products off of the market but unfortunately that doesn’t help the women who already have the products implanted in their bodies.”
SOURCE: Blizzard, McCarthy & Nabers, LLP
Blizzard, McCarthy & Nabers, LLP Ed Blizzard, 1-800-349-0127
Copyright Business Wire 2012